5 Analysts Have This to Say About Ocular Therapeutix
Portfolio Pulse from Benzinga Insights
Ocular Therapeutix (NASDAQ:OCUL) has received 2 bullish and 3 somewhat bullish ratings from analysts in the last quarter. The average 12-month price target for the stock is $12.8, up 19.96% from the previous average of $10.67.
June 13, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ocular Therapeutix has received positive analyst ratings, with an average 12-month price target of $12.8, up 19.96% from the previous average.
The article mentions that Ocular Therapeutix has received positive analyst ratings in the last quarter, with 2 bullish and 3 somewhat bullish ratings. The average 12-month price target has increased by 19.96% from the previous average, indicating a positive outlook for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100